Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations

Article abstract of DOI:10.1016/j.bmcl.2007.05.030

Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective β₃ agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent α₁ adrenergic